@article{01K5TSXR5A8TD36WTZ7RS1241Q,
  abstract     = {{Influenza vaccines are the primary strategy to prevent severe influenza disease; however, their efficacy is often suboptimal, particularly in older adults (OAs). LiteVax Adjuvant (LVA), a novel adjuvant containing carbohydrate fatty-acid monosulphate ester (CMS) as the active ingredient, has demonstrated a favourable safety profile and enhanced immunogenicity when combined with a low-dose seasonal influenza vaccine in adults aged 18 to 50 years in a first-in-human phase 1 study. The present study investigates the reactogenicity and immunogenicity of CMS-based adjuvanted seasonal influenza vaccine in OAs, with a comparison to responses in younger adults (YAs). In this phase 1b, double-blind, active-controlled clinical trial, 36 YAs (18–50 years) and 48 OAs (≥60 years) were randomized (1:1:1) to receive either 0.5 mg or 1 mg LVA combined with VaxigripTetra, or VaxigripTetra alone. Solicited adverse events (AEs) were recorded using an electronic diary for 7 days following vaccination. Hemagglutination inhibition (HI) titers against four influenza strains were measured at baseline (pre-vaccination) and at 7-, 28-, and 180-days post-vaccination. All 24 YAs and 31 out of 32 OAs receiving CMS-based adjuvanted vaccines reported pain post-vaccination, compared to 8/12 YAs and 4/16 OAs receiving VaxigripTetra. Systemic AEs were more frequently reported among YAs receiving CMS-based adjuvanted vaccines (22/24) compared to those receiving VaxigripTetra (8/12). In OAs, the number of systemic AEs was similar regardless of CMS-based adjuvant administration. Most AEs were mild to moderate and resolved within 3 days. Both CMS-based adjuvanted formulations elicited increased HI titers at Day 7, peaking at Day 28, with a decline thereafter that remained above baseline at Day 180. In YAs, HI titers were comparable between the CMS-based adjuvanted and non-adjuvanted vaccines across all strains and timepoints. In contrast, CMS-based adjuvanted vaccination in OAs induced higher HI titers at Days 28 and 180 for all influenza strains tested. LVA shows an acceptable safety profile in both age cohorts and enhances humoral immune responses in older adults. The 1 mg dose of LVA was more immunogenic, highlighting its potential utility in this target population. Future research will focus on elucidating the mechanisms underlying the immunostimulatory effect of the CMS-based adjuvant.}},
  articleno    = {{922}},
  author       = {{D'Onofrio, Valentino and Jacobs, Bart and Alhatemi, Azhar and De Gussem, Simon and Verstraete, Marjolein and Porrez, Sharon and Willems, Anthony and De Boever, Fien and Waerlop, Gwenn and Leroux-Roels, Geert and Michels, Els and Vanni, Francesca and Manenti, Alessandro and Platenburg, Peter Paul and Hilgers, Luuk and Leroux-Roels, Isabel}},
  issn         = {{2076-393X}},
  journal      = {{VACCINES}},
  keywords     = {{adjuvant,influenza vaccine,immunogenicity,safety,reactogenicity,older adults,RESPONSES}},
  language     = {{eng}},
  number       = {{9}},
  pages        = {{18}},
  title        = {{A novel carbohydrate fatty-acid monosulphate ester, squalane-in-water adjuvant is safe and enhances inactivated influenza vaccine immunogenicity in older adults}},
  url          = {{http://doi.org/10.3390/vaccines13090922}},
  volume       = {{13}},
  year         = {{2025}},
}

Altmetric

View in Altmetric

Web of Science

Times cited: